Papers/PMID:34798892
Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial.
BMC complementary medicine and therapies2021The record
3 findings · 1 compound · 3 endpoints
What it reported
How to read these marksWhat moved
3 findings
Vaccinium macrocarpon — decreases triglycerides
Evidence strength: moderate.Finding“The mean after-intervention levels of total cholesterol (p < 0.001) and triglyceride (p = 0.01) were significantly lower in the intervention group compared with the placebo group.”
Quoted verbatim from Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial.. - Study
- RCT
- Dose
- 144 mg cranberry capsule for 6 months
- Population
- Patients with non-alcoholic fatty liver disease, parallel-group randomized placebo-controlled trial, post-intervention level at 6 months
Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial.2021PMID:3479889210.1186/s12906-021-03436-6Permalink
Vaccinium macrocarpon — decreases total cholesterol (TC)
Evidence strength: moderate.Finding“The mean after-intervention levels of total cholesterol (p < 0.001) and triglyceride (p = 0.01) were significantly lower in the intervention group compared with the placebo group.”
Quoted verbatim from Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial.. - Study
- RCT
- Dose
- 144 mg cranberry capsule for 6 months
- Population
- Patients with non-alcoholic fatty liver disease, parallel-group randomized placebo-controlled trial, post-intervention level at 6 months
Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial.2021PMID:3479889210.1186/s12906-021-03436-6Permalink
Vaccinium macrocarpon — decreases HOMA-IR
Evidence strength: moderate.Finding“At the end of the study, the mean insulin and HOMA-IR levels were significantly lower in the cranberry group compared with the placebo group.”
Quoted verbatim from Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial.. - Study
- RCT
- Dose
- 144 mg cranberry capsule for 6 months
- Population
- Patients with non-alcoholic fatty liver disease, parallel-group randomized placebo-controlled trial, end of 6-month intervention
Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial.2021PMID:3479889210.1186/s12906-021-03436-6Permalink